NCT00872482 - A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2011

Conditions

Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG

nimotuzumab

Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.

Trial Locations (15)

34655

Florida Cancer Institute - New Hope, New Port Richey

55426

Park Nicollet Institute - Frauenshuh Cancer Center, Saint Louis Park

98004

Overlake Hospital Medical Center, Bellevue

T2N4N2

Tom Baker Cancer Center, Calgary

V1Y 5L3

Cancer Centre for the Southern Interior, Kelowna

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

L4M 6M2

Royal Victoria Hospital, Barrie

N6A-4L6

London Regional Cancer Center, London

M5G-2M9

Princess Margaret Hospital, Toronto

H1T-2M4

Hopital Maisonneuve-Rosemont, Montreal

G1H 2J6

Hotel Dieu Hospital, Québec

Unknown

Hospital Clínico Quirúrgico Hermanos Ameijeiras, Centro Habana

Hameed Latif Hospital, Lahore (HLH), Town

Nuclear Medicine and Radiation Oncology Institute (NORI), Islamabad

Severance Hospital, Seoul